恒瑞医药：2024年净利润同比增长28.93% 拟10派8.317元

Group 1 - The core viewpoint of the announcement indicates that Heng Rui Pharmaceutical (600276) expects a decline in operating revenue for 2024, projected at 22.047 billion yuan, representing a year-on-year decrease of 17.01% [1] - The net profit attributable to shareholders of the listed company is forecasted to be 1.684 billion yuan for 2024, showing a year-on-year increase of 28.93% [1] - The company plans to distribute a total cash dividend of 500 million yuan (including tax) for the 2024 fiscal year, in addition to the 250 million yuan (including tax) already distributed in the first half of 2024, leading to a total fixed cash dividend of 750 million yuan for the year [1] Group 2 - The special cash dividend amount is set at 30 million yuan (including tax) [1] - The total cash dividend proposed for 2024 is 530 million yuan (including tax), with an expected distribution of 0.8317 yuan (including tax) per share to all shareholders based on the total share capital after deducting the shares repurchased [1]